Curis Reports Q3 2026 Net Loss of $8.1 Million; Advances Emavusertib Studies

Curis reported no revenue and a net loss of $8.1 million, or $1.94 per share, for the third quarter of 2026. The company is enrolling patients in studies of emavusertib for chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL). Initial data from the CLL study are ex…